Research Article
Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease
| Study | Raju et al. | Deftereos et al. | LoDoCo | COLIN | LoDoCo-MI | COLCOT | LoDoCo-2 | COPS |
| Countries | Canada | Greece | Australia | France | Australia | 12 countries | Australia and Netherlands | Australia | Total no. of Pts | 82 | 222 | 532 | 44 | 237 | 4745 | 5522 | 795 | Year | 2012 | 2013 | 2013 | 2017 | 2019 | 2019 | 2020 | 2020 | Population | ACS or acute ischemic stroke | Diabetes, age 40–80, undergoing PCI with a BMS | Clinically stable CAD for ≥6 months | STEMI | MI | MI | Chronic CAD | ACS | Colchicine dose | 1 mg once daily | 0.5 mg twice daily | 0.5 mg once daily | 1 mg once daily | 0.5 mg daily | 0.5 mg daily | 0.5 mg daily | 0.5 mg twice daily for 1 month, followed by 0.5 mg once daily for 11 months | Comparator | Placebo | Placebo | Usual care | Usual care | Placebo | Placebo | Placebo | Placebo | Duration of therapy (months) | 1 | 6 | 24 | 1 | 1 | 19.6 | Not specified | 12 | Follow-up (months) | 1 | 6 | 36 | 1 | 1 | 22.6 | 28.6 | 13.3 | Primary outcome | hs-CRP level | In-stent restenosis | ACS, OHCA, or noncardioembolic ischemic stroke | CRP peak value during index hospitalization | hs-CRP level ≥2 mg/L | CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring revascularization | CV death, MI, ischemic stroke, or ischemia-driven coronary revascularization | All-cause mortality, ACS, unplanned urgent revascularization, or noncardioembolic ischemic stroke | Source of funding | Academic | Not specified | Academic | None | Academic | Academic | Academic | Academic |
|
|
ACS: acute coronary syndrome; BMS: bare metal stent; CAD: coronary artery disease; CRP: C-reactive protein; CV death: cardiovascular death; hs-CRP: high-sensitivity C-reactive protein; MACE: major adverse cardiovascular events; MI: myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.
|